SCHEMBL17393992

SCHEMBL17393992

CC(C)(C)OC(=O)N1CCCC1CS(=O)(=O)c1ccc(B2OC(C)(C)C(C)(C)O2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.43
APP P05067 1/20 0.42
HTR1A P08908 1/20 0.42
ADRA2A P08913 1/20 0.42
DRD2 P14416 1/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
SLC6A2 P23975 1/20 0.42
HRH2 P25021 1/20 0.42
HTR1D P28221 1/20 0.42
HTR1B P28222 1/20 0.42
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42
HTR7 P34969 1/20 0.42
DRD3 P35462 1/20 0.42
OPRK1 P41145 1/20 0.42
HTR2B P41595 1/20 0.42
PSEN1 P49768 1/20 0.42
SLC6A3 Q01959 1/20 0.42
TMEM97 Q5BJF2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17393993 1.00 USP30 (0.43) USP30APPHTR1AADRA2ADRD2
SCHEMBL17394511 0.86 KDM1A (0.44) USP30APPHTR1AADRA2ADRD2
SCHEMBL17394512 0.86 KDM1A (0.44) USP30APPHTR1AADRA2ADRD2
SCHEMBL12033334 0.84 USP30 (0.45) USP30MEN1KMT2AFPR3FPR2
SCHEMBL17393936 0.84 USP30 (0.50) USP30FPR3FPR2KDM1AHSD11B1
SCHEMBL16014969 0.83 USP30 (0.51) USP30
SCHEMBL1763578 0.82 LMNA (0.47) APPHTR1AADRA2ADRD2ADRA2B
SCHEMBL1763583 0.82 LMNA (0.47) APPHTR1AADRA2ADRD2ADRA2B
SCHEMBL17393969 0.82 AAK1 (0.46) USP30HRH2FPR3FPR2KDM1A
SCHEMBL16491262 0.82 AAK1 (0.46) USP30HRH2FPR3FPR2KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2964635-B1 ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2018-05-02 EP disclosed
US-9693997-B2 Antiviral compounds HOFFMANN-LA ROCHE INC. (US) 2017-07-04 US disclosed
US-20160000760-A1 ANTIVIRAL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160000760-A1 ANTIVIRAL COMPOUNDS HAVCR2, EIF2AK2, MAVS USP30 2477/4885APP 4799/4885HTR1A 3516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.